Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma

Cancer Research

Volumn 65, Issue 2, 2005, Pages 587-595

  Guidoboni, Massimo ^a   Zancai, Paola ^a   Cariati, Roberta ^a   Rizzo, Silvana ^a   Dal Col, Jessica ^a   Pavan, Alessandro ^a   Gloghini, Annunziata ^a   Spina, Michele ^a   Cuneo, Antonio ^b   Pomponi, Fabrizio ^c   Bononi, Antonio ^d   Doglioni, Claudio ^e   Maestro, Roberta ^a   Carbone, Antonino ^a   Boiocchi, Mauro ^a   Dolcetti, Riccardo ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c SAN BORTOLO HOSPITAL   (Italy)

^d GENERAL HOSPITAL   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CD40 LIGAND; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1B; INTERLEUKIN 4; PROTEIN INHIBITOR; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; RETINOID X RECEPTOR; THYMIDINE;

ADULT; AGED; ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE BIOPSY; MALE; MANTLE CELL LYMPHOMA; NUCLEOSIDE TRANSPORT; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UBIQUITINATION; UPREGULATION;

AGED; ANTIGENS, CD40; CD40 LIGAND; CELL CYCLE PROTEINS; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; FEMALE; HUMANS; INTERLEUKIN-4; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS; RECEPTORS, RETINOIC ACID; TRETINOIN; TUMOR SUPPRESSOR PROTEINS;

EID: 19944431518     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol 1999;36:115-27.
2. Bosch F, Jares P, Campo E, et al. PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 1994;84:2726-32.
3. Bodrug SE, Warner BJ, Bath ML, Lindeman GJ, Harris AW, Adams JM. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J 1994;13:2124-30.
4. Ott G, Ott MM, Kalla J, et al. Genetic lesions in mantle cell lymphoma. Recent Results Cancer Res 1997;143:307-19.
5. Galibert L, Durand I, Banchereau J, Rousset F. CD40-activated surface IgD-positive lymphocytes constitute the long term IL-4-dependent proliferating B cell pool. J Immunol 1994;152:22-9.
6. Andersen NS, Larsen JK, Christiansen J, et al. Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures. Blood 2000;96:2219-25.
7. Visser HPJ, Tewis M, Willemze R, Kluin-Nelemans JC. Mantle cell lymphoma proliferates upon IL-10 in the CD40 system. Leukemia 2000;14:1483-9.
8. Castillo R, Mascarenhas J, Telford W, Chadburn A, Friedman SM, Schattner EJ. Proliferative response of mantle cell lymphoma cells stimulated by CD40 ligation and IL-4. Leukemia 2000;14:292-8.
9. Mangelsdorf DJ, Kliewer SA, Kakizuka A, Umesono K, Evans RM. The retinoid receptors. In: Sporn M, Roberts AB, Goodman DS, editors. The retinoids, Biology, chemistry and medicine. New York: Raven Press;1995. p. 319-49.
10. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996;10:940-54.
11. Collins SJ. The role of retinoids and retinoic acid receptors in normal hematopoiesis. Leukemia 2002;16:1896-905.
12. Langenfeld J, Kiyokawa H, Sekula D, Boyle J, Dmitrovsky E. Posttranslational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism. Proc Natl Acad Sci U S A 1997;94:12070-4.
13. Boyle JO, Langenfeld J, Lonardo F, et al. Cyclin D1 proteolysis: a retinoid chemoprevention signal in normal, immortalized, and transformed human bronchial epithelial cells. J Natl Cancer Inst (Bethesda) 1999;91:373-9.
14. Spinella MJ, Freemantle SJ, Sekula D, Chang JH, Christie AJ, Dmitrovsky E. Retinoic acid promotes ubiquitination and proteolysis of cyclin D1 during induced tumor cell differentiation. J Biol Chem 1999;274:22013-8.
15. Liu M, Iavarone A, Freedman LP. Transcriptional activation of the human p21(WAF1/CIP1) gene by retinoic acid receptor. Correlation with retinoid induction of U937 cell differentiation. J Biol Chem 1996;271:31723-8.
16. Li Y, Lin B, Agadir A, et al. Molecular determinants of AHPN (CD437)-induced growth arrest and apoptosis in human lung cancer cell lines. Mol Cell Biol 1998;18: 4719-31.
17. Suzui M, Masuda M, Lim JT, Albanese C, Pestell RG, Weinstein IB. Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21 (CIP1) and inhibition of expression of cyclin D1. Cancer Res 2002;62:3997-4006.
18. Pomponi F, Cariati R, Zancai P, et al. Retinoids irreversibly inhibit in vitro growth of Epstein-Barr virus-immortalized B lymphocytes. Blood 1996;88:3147-58.
19. 1 regulatory proteins: p27Kip-1 upregulation is a relevant early event. Oncogene 1998;17: 1827-36.
20. Baldassarre G, Boccia A, Bruni P, et al. Retinoic acid induces neuronal differentiation of embryonal carcinoma cells by reducing proteasome-dependent proteolysis of the cyclin-dependent inhibitor p27. Cell Growth Differ 2000;11:517-26.
21. 1 arrest is associated with induction of p27(Kip1) and inhibition of cyclin-dependent kinase 3 in human lung squamous carcinoma CH27 cells. Exp Cell Res 2000;258:322-31.
22. Dow R, Hendley J, Pirkmaier A, Musgrove EA, Germain D. Retinoic acid-mediated growth arrest requires ubiquitylation and degradation of the F-box protein Skp2. J Biol Chem 2001;276:45945-51.
23. Zhang D, Vuocolo S, Masciullo V, et al. Cell cycle genes as targets of retinoid induced ovarian tumor cell growth suppression. Oncogene 2001;20:7935-44.
24. Dimberg A, Bahram F, Karlberg I, Larsson LG, Nilsson K, Oberg F. Retinoic acid-induced cell cycle arrest of human myeloid cell lines is associated with sequential down-regulation of c-Myc and cyclin E and posttranscriptional up-regulation of p27(Kip1). Blood 2002;99:2199-206.
25. Evans TRJ, Kaye SB. Retinoids: present role and future potential. Br J Cancer 1999;80:1-8.
26. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001;1:181-93.
27. Warrell RP. Pathogenesis and management of acute promyelocytic leukemia. Annu Rev Med 1996;47:555-65.
28. Cariati R, Zancai P, Quaia M, et al. Retinoic acid induces persistent, RARα-mediated anti-proliferative responses in Epstein-Barr virus-immortalized B lymphoblasts carrying an activated C-MYC oncogene but not in Burkitt's lymphoma cell lines. Int J Cancer 2000; 86:375-84.
29. Sundaresan A, Claypool K, Mehta K, Lopez-Berestein G, Cabanillas F, Ford RJ Jr. Retinoid-mediated inhibition of cell growth with stimulation of apoptosis in aggressive B-cell lymphomas. Cell Growth Differ 1997;8:1071-82.
30. Jadayel DM, Lukas J, Nacheva E, et al. Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519). Leukemia 1997;11:64-72.
31. Daibata M, Kubonishi I, Eguchi T, Yano S, Ohtsuki Y, Miyoshi I. The establishment of Epstein-Barr virus nuclear antigen-positive (SP-50B) and Epstein-Barr virus nuclear antigen-negative (SP-53) cell lines with t(11;14)(q13;q32) chromosome abnormality from an intermediate lymphocytic lymphoma. Cancer 1989;64:1248-53.
32. Amin HM, McDonnell TJ, Medeiros LJ, et al. Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med 2003;127:424-31.
33. Lyons AB, Parish CR. Determination of lymphocyte division by flow cytometry. J Immunol Methods 1994; 171:131-7.
34. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction. Anal Biochem 1987;162:156-9.
35. Clodi K, Snell V, Zhao S, Cabanillas F, Andreeff M, Younes A. Unbalanced expression of Fas and CD40 in mantle cell lymphoma. Br J Haematol 1998;103:217-9.
36. Lam N, Sugden B. CD40 and its viral mimic, LMP1: similar means to different ends. Cell Signal 2003;15:9-16.
37. Sakashita A, Kizaki M, Pakkala S, et al. 9-cis-retinoic acid: effects on normal and leukemic hematopoiesis in vitro. Blood 1993;81:1009-16.
38. Quintanilla-Martinez L, Davies-Hill T, Fend F, et al. Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis. Blood 2003;101:3181-7.
39. Quintanilla-Martinez L, Thieblemont C, Fend F, et al. Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor. Am J Pathol 1998; 153:175-82.
40. Kurie JM, Lee JS, Griffin T, et al. Phase I trial of 9-cis retinoic acid in adults with solid tumors. Clin Cancer Res 1996;2:287-93.
41. Miller VA, Rigas JR, Benedetti FM, et al. Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid. Clin Cancer Res 1996;2:471-5.
42. Adamson PC, Widemann BC, Reaman GH, et al. A phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer: a joint Pediatric Oncology Branch, National Cancer Institute, and Children's Cancer Group study. Clin Cancer Res 2001;7:3034-9.
43. Lawrence JA, Adamson PC, Caruso R, et al. Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic, and biomarker evaluations. J Clin Oncol 2001;19:2754-63.